Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression.
about
Heparin in malignant glioma: review of preclinical studies and clinical resultsDevelopment and characterization of a microfluidic model of the tumour microenvironment.NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiformePrognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaginRelationship between Apparent Diffusion Coefficients and MR Spectroscopy Findings in High-Grade Gliomas.Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas.Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in GliomaThe role of chemoattractant receptors in shaping the tumor microenvironment.Integrating diverse genomic data using gene setsHypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing.The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.The expression of hypoxia-inducible factor-1 in primary brain tumors.Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgeryNovel chemotherapeutic agents for the treatment of glioblastoma multiforme.Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas.'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis.Multifunctional protein APPL2 contributes to survival of human glioma cells.Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiformeIntravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastomaIntegrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis.Brain tumors and epilepsy: pathophysiology of peritumoral changes.Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome.Angiogenesis and invasion in glioma.Aberrant signaling pathways in glioma.GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms.Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questionsFAT1 is a novel upstream regulator of HIF1α and invasion of high grade glioma.Role of vincristine in the inhibition of angiogenesis in glioblastoma.Investigation of hypoxia conditions using oxygen-enhanced magnetic resonance imaging measurements in glioma models.A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of GliomaHyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.Imaging the impact of Nox4 in cycling hypoxia-mediated U87 glioblastoma invasion and infiltration.Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma.Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance.A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma.
P2860
Q26821781-47D7365C-C86C-4D78-A274-7CE3D39274F8Q28315265-F4CC7E05-3D42-46F1-AC3F-D1E682F80DACQ28477083-16BB69B1-A9F4-450B-9516-FC276840365EQ30871297-BA649837-DD87-4DC3-AEA3-01E4C7A33F5AQ31077412-3786111C-5A02-4291-B3C3-AAF822C9E206Q33635374-FF12F733-4FFE-4AC7-814E-72FAACC11465Q33876259-1A5B1979-BB16-4FAE-A009-DE8C4E881059Q33993124-DBF3EEB6-1AF9-4F16-9DF1-F38AF62C7347Q34054123-19D8D699-7DD2-4755-9CD1-74CC92D02A37Q34107629-75EAFD05-C3BD-4092-98D6-2CC6BB425F15Q34620966-70321FBE-7B24-467F-A618-8FB1E98479CDQ34621903-43D86C22-2075-4370-9D0D-AE27EA1DCDDCQ34633386-5DE8D758-1E44-47E9-8748-CA89F2D24C0BQ34646194-8C4A3F2D-6841-4446-8042-29D5CDBDAB52Q35566187-7A6C5E0A-02D2-4308-8350-3E0D9CDAC4F9Q35594029-B843C225-E516-4F45-9B04-CFB1E2FE5894Q36061803-AE8C5365-99B0-4663-96D4-D3C0D5C03A1EQ36389363-605F0C1F-347C-4A95-989D-1C848C670943Q36510818-2B2E9D7C-1D62-40FF-9DCC-316D1C84E78DQ36558037-85DF358B-7304-4F2F-89C0-8D3A934C1E01Q36952855-0E076F63-AC38-424E-9683-1FE054B9375EQ37029795-D607C904-2A47-48BE-B4E0-A5CCC43EB0C8Q37132758-74B760F5-93BA-4798-83E6-BF12AA46CD84Q37389299-9DAD7BC9-23E1-4C54-BFBF-72BD5FAD1A47Q37439503-4558FE04-86FD-4B6F-8534-AD6C6C776055Q37492118-1150D474-99F4-4E91-9B71-73B2E2E5FE18Q37827399-0A57F20C-01EC-4D96-8FC6-E77A3F2A827BQ38161369-43B7907F-169F-476F-91CA-1C7C0223CD20Q38197021-D6CD8777-212A-4AB3-A862-AD80B81E2D52Q38311379-51E51A2E-2BE3-4D47-B51A-25B83D4CEEC3Q38548208-4E59103C-6E63-4BDA-A46F-F0DCCB7160F0Q38751296-A0D50AA5-7C9A-4D83-B053-7D30A3B8A5A3Q38754878-28A5790B-4BA5-4C59-B49B-6B82F151A87CQ38832528-D3EA8349-AAAF-4213-B559-8242A605B8E8Q38843065-A7A83ABA-FEB6-485E-8909-39B56BB6DC13Q39319634-B5BDE9F5-AE7E-431F-A7BF-5BEB6056A53CQ39484108-F24E2B8B-A741-49FD-9318-9344D93EF8D1Q39559394-019989E3-DAE4-4D34-8B89-DFDA0F148D89Q43181029-E93E1101-B327-433A-B7BF-6C5ACF80E06EQ47784163-5E182F4B-620F-452C-B013-49142B4D83D8
P2860
Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Malignant glioma physiology: c ...... its role in tumor progression.
@ast
Malignant glioma physiology: c ...... its role in tumor progression.
@en
type
label
Malignant glioma physiology: c ...... its role in tumor progression.
@ast
Malignant glioma physiology: c ...... its role in tumor progression.
@en
prefLabel
Malignant glioma physiology: c ...... its role in tumor progression.
@ast
Malignant glioma physiology: c ...... its role in tumor progression.
@en
P1476
Malignant glioma physiology: c ...... its role in tumor progression.
@en
P2093
Daniel J Brat
Timothy B Mapstone
P304
P356
10.7326/0003-4819-138-8-200304150-00014
P407
P577
2003-04-01T00:00:00Z